Generalized Pustular Psoriasis (GPP)Symptoms, Doctors, Treatments, Advances & More
Generalized Pustular Psoriasis (GPP) Overview
Learn About Generalized Pustular Psoriasis (GPP)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Bruce Strober is a Dermatologist practicing medicine in Canton, Connecticut. Dr. Strober is rated as an Elite provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Psoriasis, Plaque Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP).
Alice Gottlieb is a Dermatologist practicing medicine in New York, New York. Dr. Gottlieb is rated as an Elite provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). She is also highly rated in 35 other conditions, according to our data. Her clinical expertise encompasses Psoriasis, Plaque Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP).
Boni Elewski is a Dermatologist practicing medicine in Birmingham, Alabama. Dr. Elewski is rated as an Elite provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Ringworm, Psoriasis, Plaque Psoriasis, and Generalized Pustular Psoriasis (GPP).
Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.
Summary: Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
